RNUGF Projected Dividend Yield

Ord GBP 0.01/Reneuron Group plc ( OTCBB : RNUGF )

Reneuron Group and its subsidiaries are engaged in the research and development of therapies using stem cells. Co.'s products include: CTX cells for stroke disability, which is Co.'s therapeutic candidate for the treatment of patients left disabled by the effects of a stroke; human retinal progenitor cells (hRPCs) for retinitis pigmentosa (RP), which is Co.'s therapeutic hRPC candidate for the treatment of RP, a blindness-causing disease of the retina; hRPCs for cone-rod dystrophy, which is a hRPC therapeutic candidate across a range of genetic diseases of the eye; and CTX-derived exosomes, which is Co.'s exosomes nanomedicine platform that generates early pre-clinical data in cancer.

20 YEAR PERFORMANCE RESULTS